Home › Funds › Paradigm Biocapital Advisors LP › ACHV
Paradigm Biocapital Advisors LP position in ACHV
ACHIEVE LIFE SCIENCE INC · Health Care
Paradigm Biocapital Advisors LP reported holding 4,951,856 shares of ACHV (ACHIEVE LIFE SCIENCE INC) in its Q3 2026 13F filing — a position valued at US$40.1M, representing 0.80% of its reported portfolio and ranking #19 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed ACHV holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's ACHV position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in ACHV in Q2 2026 at 4,951,856 shares (US$32.3M). The position peaked in Q3 2026 at 4,951,856 shares, worth US$40.1M. Across 2 filings, Paradigm Biocapital Advisors LP held the position steady without any share-count change. The most recent filing (Q3 2026) shows 4,951,856 shares valued at US$40.1M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 4.95M | $32.34M | New |
| Q3 2026 | 4.95M | $40.06M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ACHV and 13F data
ACHV (ACHIEVE LIFE SCIENCE INC) is a Health Care company. 69 other funds we track also report a position in ACHV — the largest reported positions include Frazier Life Sciences Management, L.P. (US$49.7M), TPG GP A, LLC (US$44.9M), venBio Partners LLC (US$38.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ACHV
- Frazier Life Sciences Management, L.P. 7.61M sh · $49.72M · Q2 2026
- TPG GP A, LLC 6.88M sh · $44.91M · Q2 2026
- venBio Partners LLC 5.91M sh · $38.62M · Q2 2026
- Propel Bio Management, LLC 3.86M sh · $31.26M · Q3 2026
- Vivo Capital, LLC 2.75M sh · $22.26M · Q3 2026
- Venrock Adviser, LLC 2.75M sh · $17.96M · Q2 2026
- Logos Global Management LP 1.00M sh · $8.09M · Q3 2026
- Simplify Asset Management Inc. 932.11K sh · $7.54M · Q3 2026
- Spruce Street Capital LP 736.64K sh · $5.96M · Q3 2026
- KVP Capital Advisors, LP 462.36K sh · $3.74M · Q3 2026
- Blue Owl Capital Holdings LP 412.65K sh · $3.34M · Q3 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held ACHV?
Paradigm Biocapital Advisors LP has disclosed ACHV holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Paradigm Biocapital Advisors LP's current position in ACHV?
As of Q3 2026, Paradigm Biocapital Advisors LP holds 4.95M shares of ACHV (ACHIEVE LIFE SCIENCE INC), valued at $40.06M, representing 0.80% of its reported portfolio and ranking #19.
Has Paradigm Biocapital Advisors LP been buying or selling ACHV?
In the latest 13F filing (Q3 2026), Paradigm Biocapital Advisors LP held unchanged its position in ACHV. The position peaked in Q3 2026 at 4.95M shares.
Which other funds hold ACHV?
Other major institutional holders of ACHV include Frazier Life Sciences Management, L.P., TPG GP A, LLC, venBio Partners LLC, among 69 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.